Jardiance carries a retail price of roughly $600 to $750 per month at most U.S. pharmacies, and some retailers charge closer to $850. That adds up to $9,000 or more per year for patients paying out of pocket. Several forces keep the price this high: patent protection that blocks generic competition, a supply chain built on hidden rebates, and a U.S. regulatory system that doesn’t cap drug prices the way other countries do.
No Generic Competition Yet
The single biggest reason Jardiance costs what it does is that no generic version is available in the United States. Boehringer Ingelheim, the manufacturer, holds multiple patents on the drug. The earliest patents begin expiring in 2027, but later ones stretch all the way to 2034. As long as those patents hold, no other company can legally sell a cheaper copy.
There was briefly an approved generic from one manufacturer, Zydus Pharmaceuticals, but it was discontinued in 2022 and never reached the market in a meaningful way. Meanwhile, Jardiance’s main competitor in the same drug class, Farxiga, already has a generic version (dapagliflozin) available. Jardiance does not, which removes the pricing pressure that generics typically create. When a generic enters the market, prices often drop 80% or more within a few years. Until that happens, the manufacturer can set essentially whatever price it wants.
The U.S. Pricing System Itself
Jardiance costs dramatically less outside the United States. In Canada, the same 30-tablet supply runs about $130, a savings of up to 83% compared to U.S. retail prices. That gap exists because most other wealthy countries negotiate or regulate pharmaceutical prices at a national level. The U.S. historically has not.
The American drug pricing system involves a chain of middlemen. The manufacturer sets a high list price, then offers confidential rebates to pharmacy benefit managers (PBMs), the companies that negotiate drug coverage on behalf of insurers. Those rebates can be substantial, meaning the “net price” insurers actually pay is lower than what you see on a pharmacy shelf. But the rebates don’t always flow down to the patient. If you’re uninsured, underinsured, or stuck in the deductible phase of a high-deductible plan, you face something close to the full list price. The system essentially rewards having good insurance and penalizes everyone else.
Clinical Value Justifies the Price, to a Point
Jardiance isn’t just a blood sugar medication anymore. It started as a treatment for type 2 diabetes, but landmark clinical trials showed it also reduces the risk of cardiovascular death, heart failure hospitalization, and kidney disease progression. For patients with diabetic kidney disease specifically, adding Jardiance to standard care resulted in fewer major cardiac events and slower kidney decline over time.
Pharmaceutical companies and health economists use these broader benefits to argue the drug is worth its cost. One cost-effectiveness analysis based on the major EMPA-REG OUTCOME trial found that Jardiance added about 0.67 quality-adjusted life years per patient over a lifetime, at an additional cost of roughly $17,300. That works out to about $26,000 per quality-adjusted life year gained, well below the $50,000 threshold that economists generally consider good value. In fact, 91% of the simulations in that analysis fell under the $50,000 mark.
This is the argument the manufacturer leans on: the drug prevents expensive hospitalizations and extends life, so its price reflects genuine clinical value. That argument has merit from a health-system perspective, but it doesn’t change the monthly bill for someone staring at a $750 pharmacy receipt.
Medicare Negotiations Are Coming
Jardiance was one of the first ten drugs selected for price negotiation under the Inflation Reduction Act. This is a new program that, for the first time, allows Medicare to directly negotiate prices with pharmaceutical manufacturers. The negotiated price for Jardiance is set to take effect on January 1, 2026.
This will matter most for Medicare Part D enrollees, who make up a large share of Jardiance users since type 2 diabetes and heart failure are more common in older adults. The negotiated price won’t directly change what privately insured or uninsured patients pay, but it could put downward pressure on the broader market over time.
Ways to Lower Your Cost Now
If you’re paying close to the list price, there are a few practical options. The manufacturer offers a savings card program that can significantly reduce copays for commercially insured patients. Discount pharmacy programs and coupon sites sometimes bring the price below $400. Shopping across pharmacies helps too, since prices vary by hundreds of dollars between retailers for the exact same medication.
If you’re on Medicare or Medicaid, manufacturer coupons typically don’t apply, but the upcoming negotiated price in 2026 should bring relief. Some patients also ask their prescriber about Farxiga’s generic, dapagliflozin, which belongs to the same drug class and may be a less expensive alternative depending on the specific condition being treated. The two drugs aren’t identical, but they work through the same mechanism and have overlapping uses.
The core problem is structural: a patented drug with proven benefits in a pricing system that doesn’t regulate costs. Until generic competition arrives or government-negotiated prices expand beyond Medicare, the list price is unlikely to drop on its own.